Wednesday, July 8, 2026

Drug profile · INN

conivaptan hydrochloride

conivaptan hydrochloride (VAPRISOL) is a vasopressin v1a receptor antagonist. Associated with CUMBERLAND PHARMACEUTICALS INC. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 7
Pipeline programs 6
News articles 0
Drug details — conivaptan hydrochloride
US status
approved
Class
Route
INJECTION
Patents
7
Programs
6
Data quality
0.89

Quick answer

conivaptan hydrochloride (VAPRISOL) is a vasopressin v1a receptor antagonist. Associated with CUMBERLAND PHARMACEUTICALS INC. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN conivaptan hydrochloride
Brand VAPRISOL
Mechanism Vasopressin V1a receptor antagonist
Target Vasopressin V1a receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Vasopressin V1a receptor antagonist

Primary target: Vasopressin V1a receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Conivaptan hydrochloride Phase 3 · Cumberland Pharmaceuticals · Hyponatremia
  2. conivaptan Phase 2 · Cumberland Pharmaceuticals · Chronic Heart Failure
  3. conivaptan Phase 2 · Cumberland Pharmaceuticals · Liver Cirrhosis
  4. conivaptan hydrochloride Phase 1 · Cumberland Pharmaceuticals · Kidney Diseases
  5. conivaptan hydrochloride Phase 1 · Cumberland Pharmaceuticals · Liver Disease
  6. Conivaptan Approved · Cumberland Pharmaceuticals · Hyponatremia

Related & competitor drugs

  1. vasopressin tannate Vasopressin V1a receptor agonist
  1. US 12161632

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10925860

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10583126

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10314824

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 10016399

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9693998

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 6727286

    Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid

    Expires Mon Apr 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is conivaptan hydrochloride?

conivaptan hydrochloride (VAPRISOL) is a vasopressin v1a receptor antagonist. Associated with CUMBERLAND PHARMACEUTICALS INC. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for conivaptan hydrochloride?

VAPRISOL is a marketed brand name for conivaptan hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of conivaptan hydrochloride?

conivaptan hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.